IRADIMED CORP
IRMDNASDAQTrading Snapshot
- Day Range
- $85.63 – $86.96
- 52-Week Range
- $67.84 – $107.90
- Volume
- $2.22B
- Avg Volume
- $2.86B
- Shares Outstanding
- 12.8M
- Next Earnings
- Nov 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $84M
- Last Q Revenue
- $20M
- P/E Ratio
- 47.6
- P/S Ratio
- 12.7x
- EPS (TTM)
- $1.79
- Dividend Yield
- 1.44%
- Dilution (1yr)
- +0.7%
Why Investors Own IRMD
- ✓High-growth profile — revenue up +25.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 50% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
IRADIMED CORP
IRMD
StockOtter · stockotter.spaceAbout IRADIMED CORP
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it wi
Head-To-Head Contrast: iRadimed (NASDAQ:IRMD) & Medline (NASDAQ:MDLN)
iRadimed (NASDAQ: IRMD - Get Free Report) and Medline (NASDAQ: MDLN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their
iRadimed Corp (IRMD) Stock Down 3.8% but Still Overvalued -- GF Score: 92/100
On September 04, 2026, iRadimed Corp (IRMD) shares fell 3.8%, currently trading at $83.45. The stock has seen a notable decline, with a 52-week high of $107.90
Algert Global LLC Sells 15,062 Shares of iRadimed Corporation $IRMD
Algert Global LLC trimmed its stake in iRadimed Corporation (NASDAQ: IRMD) by 17.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm o
iRadimed Corporation (NASDAQ:IRMD) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of iRadimed Corporation (NASDAQ: IRMD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five ratings firms that are presently covering the firm, MarketBeat reports. Two equities
iRadimed Q2 Earnings Call Highlights
iRadimed NASDAQ: IRMD reported second-quarter 2026 revenue of $20.5 million, up 0.5% from a year earlier, as the company began general-release production of its new 3870 MRI IV pump system and worked through the costs as